Breast cancer discovery could help prevent recurrence

Know someone who’s been diagnosed with breast cancer? There’s a good chance that person has received hormone therapy. Estrogen receptor-positive (ER+) breast cancers account for about 75 percent of cases. Hormone therapy is one of the most common and effective treatments. However, it’s far from a cure. Some ER+ tumors develop resistance. Many patients enter remission only to see the disease return in a form that can’t be treated with hormone therapy. Now, biologists at Cold Spring Harbor (CSHL) have made a discovery that could someday help prevent breast cancer recurrence and lead to better patient outcomes.

Research from CSHL Associate Professor Camila dos Santos’ lab shows that inhibiting the BPTF protein in mice can slow ER+ cancer metastasis and restore tumors’ susceptibility to hormone therapy. The finding could have “huge implications for making cancer more treatable,” says Michael Ciccone, a former researcher in the lab. “We’re not curing cancer, but we’re forcing it into an avenue that we’re good at, which is targeting it with hormone therapies.”

Previous research had found that knocking out BPTF slows breast cancer growth but doesn’t stop tumors from forming. As such, pharmaceutical companies didn’t see much promise in the protein. However, Ciccone and his lab-mates, graduate student Dhivyaa Anandan and postdoc Deeptiman Chatterjee, saw untapped potential. To learn more, they bred a classic breast cancer mouse model with a BPTF knockout mouse. To their surprise, they found the tumors in the crossbred mice remained ER+ throughout their development.

“There isn’t any mouse model that maintains a hormone-positive cancer throughout the cycle of the tumor,” Ciccone said. When treated with tamoxifen, one of the most common hormone therapies for ER+ breast cancer, the tumors were “responding and not growing,” he said. “That’s when we realized that we were onto something.”

The team tested a combination of BPTF loss and tamoxifen in organoid systems, human breast cancer cell lines, and mouse models resistant to hormone therapy. In all cases, the combination restored sensitivity to treatment. “Our work highlights biological mechanisms that are not only very fascinating, but translatable,” Chatterjee said.

Anandan emphasized that it was the group’s fundamental approach to research that made their discoveries possible. “Cancer is often studied in a binary way,” she says. “Is it there or not? Did the tumors grow or shrink? This study showed there is far more nuance. If we don’t look at the types of tumors that are growing, how they’re growing, and where they’re spreading—all the very nuanced analyses we did—we miss so much.”

Written by: Margaret Osborne, Science Writer | publicaffairs@cshl.edu | 516-367-8455

Funding

Pershing Square Sohn Cancer Research Alliance, Simons Foundation, CSHL-Northwell Affiliation, National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences

Citation

Ciccone, M.F., et al., “Loss of BPTF restores estrogen response and suppresses metastasis of mammary tumors”, Nature Communications, October 15, 2025. DOI: 10.1038/s41467-025-64255-8

Core Facilites

“The Animal Shared Resource houses and cares for the animals essential for scientific research. Our staff perform all aspects of animal husbandry, ensure humane care, and assist researchers with highly technical procedures and protocol design and development.” — Animal Facility Director and Attending Veterinarian Rachel Rubino, DVM

“The Flow Cytometry Shared Resource offers researchers equipment, training, and assistance with cellular analysis for a variety of applications as well as cell sorting. Our staff oversees equipment maintenance and quality control, trains new users on instrument operation, and assists with assay development and data analysis. We also provide tissue culture facilities for sample preparation and cell maintenance during ongoing flow cytometry experiments.” — Director Pamela Moody

“The Microscopy Core Facility provides training, consultation, experimental design and technical assistance to investigators at CSHL in widefield, spinning disk laser scanning or point laser scanning confocal fluorescence microscopy, and super-resolution microscopy. In addition, the Microscopy Shared Resource provides customized state-of-the-art optical imaging and quantitative image analysis applications to support a wide range of scientific endeavors.” — Director Erika Wee, Ph.D.

“The Sequencing Technologies and Analysis Shared Resource provides access to an array of high throughput Next Generation Sequencing (NGS) technologies. We offer cutting-edge technology alongside convenient in-house services for a broad range of genetic analysis.” — Project Manager Sara Goodwin, Ph.D.

“The Single Cell Genomics Core Facility brings cutting-edge single-cell technologies to collaborators both inside and outside of the Laboratory. We currently specialize in single-cell transcriptomics and offer assistance in a variety of gene expression workflows, including the latest in spatial gene expression profiling technologies.” — Director Jon Preall, Ph.D.

“The Tissue Imaging Shared Resource provides a spectrum of on-demand and researcher-tailored histopathological services, including tissue sampling, processing, embedding, and sectioning, as well as H&E, special, and immunohistochemistry staining. We not only support laser-capture microdissection and whole-slide scanning, but also offer histopathology consultation and instrument training.” — Manager Kristin Milicich